At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
Deep Brain Stimulationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
VANTAGE STUDY Vercise™ Implantable Stimulator for Treating Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating Deep Brain Stimulation for Idiopathic Parkinson's Disease. Completed, enrolled 53 participants across 7 sites in 6 countries.
Detailed Summary
The purpose of this study is to document patient outcomes, including effectiveness, safety, and health economic data, for the Boston Scientific implantable deep brain stimulation (DBS) Vercise™ system for bilateral stimulation of the subthalamic nucleus (STN) in the treatment of moderate to severe idiopathic Parkinson's Disease (PD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Parkinson's Disease
CountriesAustria, France, Germany, Italy, Spain, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedOct 2010
Primary CompletionMay 2013
Study CompletionJun 2018
TodayJul 2026
First PostedOct 18, 2010
Enrollment StartOct 1, 2010
Primary CompletionMay 1, 2013
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.7 years ago
Interventions
Deep Brain Stimulationdevice
Rechargeable Deep Brain Stimulation System